HC Wainwright Reiterates Buy Rating for Jasper Therapeutics (NASDAQ:JSPR)

Jasper Therapeutics (NASDAQ:JSPR)‘s stock had its “buy” rating restated by equities researchers at HC Wainwright in a research note issued to investors on Tuesday,Benzinga reports. They presently have a $40.00 target price on the stock.

A number of other equities analysts also recently issued reports on JSPR. Royal Bank of Canada cut their price objective on shares of Jasper Therapeutics from $68.00 to $48.00 and set an “outperform” rating on the stock in a report on Thursday, January 9th. UBS Group initiated coverage on shares of Jasper Therapeutics in a research report on Thursday, February 13th. They issued a “buy” rating and a $38.00 price objective for the company. BMO Capital Markets began coverage on shares of Jasper Therapeutics in a research report on Friday, December 6th. They set an “outperform” rating and a $63.00 target price on the stock. Finally, JMP Securities restated a “market outperform” rating and issued a $70.00 target price on shares of Jasper Therapeutics in a research note on Monday, January 6th. Ten investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Jasper Therapeutics currently has a consensus rating of “Buy” and an average target price of $62.50.

Jasper Therapeutics Trading Down 2.3 %

Shares of JSPR traded down $0.12 on Tuesday, reaching $5.16. The company’s stock had a trading volume of 146,788 shares, compared to its average volume of 657,280. The stock has a market capitalization of $77.45 million, a PE ratio of -1.09 and a beta of 2.23. Jasper Therapeutics has a twelve month low of $4.55 and a twelve month high of $31.01. The firm has a fifty day moving average of $7.99 and a 200-day moving average of $16.28.

Jasper Therapeutics (NASDAQ:JSPR) last issued its quarterly earnings data on Thursday, February 27th. The company reported ($1.62) EPS for the quarter, missing the consensus estimate of ($1.27) by ($0.35). As a group, equities analysts anticipate that Jasper Therapeutics will post -4.47 EPS for the current fiscal year.

Institutional Trading of Jasper Therapeutics

A number of large investors have recently bought and sold shares of the company. BNP Paribas Financial Markets grew its stake in shares of Jasper Therapeutics by 208.6% during the 3rd quarter. BNP Paribas Financial Markets now owns 2,512 shares of the company’s stock worth $47,000 after acquiring an additional 1,698 shares during the period. MetLife Investment Management LLC lifted its holdings in Jasper Therapeutics by 129.1% during the third quarter. MetLife Investment Management LLC now owns 6,874 shares of the company’s stock valued at $129,000 after purchasing an additional 3,873 shares during the last quarter. Wells Fargo & Company MN boosted its position in Jasper Therapeutics by 106.7% during the fourth quarter. Wells Fargo & Company MN now owns 7,415 shares of the company’s stock worth $159,000 after purchasing an additional 3,828 shares during the period. EntryPoint Capital LLC purchased a new position in shares of Jasper Therapeutics in the fourth quarter worth about $223,000. Finally, Jane Street Group LLC bought a new stake in shares of Jasper Therapeutics in the third quarter valued at approximately $251,000. 79.85% of the stock is owned by hedge funds and other institutional investors.

Jasper Therapeutics Company Profile

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.